QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced it has raised nearly $44 million in a series E financing round. The new round of funding will be used primarily to complete ongoing Phase 3 and Phase 2 clinical studies of QuatRx’s two endocrine programs, Ophena™ and fispemifene, and Phase 1 clinical studies with its lipid-lowering compound, QRX-431. Each of these compounds is positioned to address markets with annual sales potentials in excess of $1 billion.

Venrock led the financing and was joined by three other new investors in QuatRx – T. Rowe Price, Catella Healthcare, and Hercules Technology Growth Capital. The company’s current investors, including Frazier Healthcare Ventures, TL Ventures, MPM Capital, InterWest Partners, Thomas Weisel Healthcare Ventures, Stockwell Capital, H&B Capital, BioMedical Ventures, Bio Fund Ventures and Twilight Venture Partners also participated in the financing.

“The strong interest we’ve received from these leading investors and the continued support from our existing investors reflect the excitement we share as we approach upcoming milestones for our clinical development programs,” said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. “This funding positions us to advance our clinical pipeline in these important therapeutic areas.”